Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia
| Autor: | Marwa F. Harras, Amani M.R. Alsaedi, Thoraya A. Farghaly, Samar J. Almehmadi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pyrimidine
Stereochemistry Antineoplastic Agents Biochemistry Structure-Activity Relationship chemistry.chemical_compound Pharmacokinetics Drug Discovery Tumor Cells Cultured Humans Potency Dinaciclib Binding site Cytotoxicity Protein Kinase Inhibitors Molecular Biology Cell Proliferation ADME Dose-Response Relationship Drug Molecular Structure Cyclin-Dependent Kinase 2 Organic Chemistry Bioavailability Molecular Docking Simulation Pyrimidines chemistry Pyrazoles Drug Screening Assays Antitumor |
| Zdroj: | Bioorganic Chemistry. 117:105431 |
| ISSN: | 0045-2068 |
| DOI: | 10.1016/j.bioorg.2021.105431 |
| Popis: | Based on the structural study of previously known CDK2 inhibitors, a new series of pyrazolo[1,5-a]pyrimidine derivatives was designed and synthesized. The target compounds were biologically assessed as potent CDK2 inhibitors and promising anti-leukemia hits. The 7-(4-Bromo-phenyl)-3-(3-chloro/2-chloro-phenylazo)-pyrazolo[1,5-a]pyrimidin-2-ylamines 5 h and 5i revealed the best CDK2 inhibitory activity with comparable potency (IC50 = 22 and 24 nM, respectively) to that of dinaciclib (IC50 = 18 nM). Additionally, both analogues showed potent activities against CDK1, CDK5 and CDK9 at nanomolar concentrations (IC50 = 28–80 nM). The anti-leukemia screening of the target compounds showed strong to moderate cytotoxicity against the used leukemia cell lines (MOLT-4 and HL-60). Compound 5 h inhibited MOLT-4 and HL-60 by 1.4 and 2.3 folds (IC50 = 0.93 and 0.80 µM), respectively, compared to dinaciclib (IC50 = 1.30 and 1.84 µM). Furthermore, compound 5i was comparable to dinaciclib against MOLT-4 and exhibited twice its activity against HL-60. Besides, the cytotoxicity of the promising analogues on normal human blood cells indicated the safety of 5h and 5i as compared to the reference dinaciclib. The pharmacokinetic properties of 5h and 5i were predicted using ADME calculations revealing good oral bioavailability and high GI absorption. The molecular docking simulations indicated, as expected, that the dinaciclib analogues can well-accommodate the CDK2 binding site, forming a variety of interactions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect